Select Abstracts

Good Response with Microsphere Radioembolization in NET Liver Mets
9/6/2017
Link to Abstract

Surgery Not Observation for Small Non-functioning NETs
9/1/2017
Link to Abstract

Yttrium-90 Microspheres for Hepatic Metastases in NETs
9/1/2017
Link to Abstract

Tumor Surgery in Advanced NETs May Enhance Survival
5/25/2017
Link to Abstract

Afinitor for G3 NE Tumors
3/1/2017
Link to Abstract

Histologic Differentiation Offers Guidance for Treatment Options in NETs
3/1/2017
Link to Abstract

Transarterial Chemoembolization with Streptozotocin for Hepatic Mets in NETs
2/1/2017
Link to Abstract

Primary Tumor Resection with Hepatic Metastasis
2/1/2017
Link to Abstract

Dacarbazine for progressive advanced NETs
August 18, 2016
Link to Abstract

Gedatolisib – dual target mTOR kinase inhibitor for NET treatment
August 12, 2016
Link to Abstract

Active surveillance vs. Surgery in Symptomless Small NETs
April 1, 2016
Link to Abstract

Combination Sugical Procedures Appear Beneficial in Select NETs
February 29, 2016
Link to Abstract

PRRT for NETs 
February 1, 2016
Link to Abstract

Surgery Improves Results Even in Metastatic Pancreatic NETs
January 1, 2016
Link to Abstract

Postive Case Study of 70 year old with insulinoma treated with PRRT
January 1, 2015
Link to Abstract

Everything Old Becomes new Again: CRP for Prognosis in Pancreatic Neuroendocrine Tumors
December 17, 2015
Link to Abstract

Portal Vein Surgery in Pancreatic NETs
November 1, 2015
Link to Abstract

Induction Therapy with (177)Lu-octreotate for Non-functioning NETs Can Provide Some Patients a Surgical Option
November 1, 2015
Link to Abstract

A Clinical Trial of the PRRT (177)Lu-octreotate Plus Afinitor for Advanced NETs
August 1, 2015
Link to Abstract

Somatostatin Analogues Plus mTOR Inhibitors (Afinitor and Sutent) for NETs
July 4, 2015
Link to Abstract

Could the FOLFOX Combination Chemotherapy Regimen be Considered as 2nd Line for Progressing Neuroendocrine Tumors ?
June 1, 2015
Link to Abstract

Combination Therapy with Torisel Plus Avastin for Pancreatic NETs
May 10, 2015
Link to Abstract

Markers of Sutent Efficacy in Metastatic NETs
March 31, 2015
Link to Abstract

Extended Afinitor Therapy in Pancreatic NETs
March 7, 2015
Link to Abstract

Sutent Regulation of Untoward Effects of a VIPoma-related Verner-Morrison syndrome: a two-patient case study
January 1, 2015
Link to Abstract

Clinical Trial: Avastin Plus Fluorouracil and Streptozocin for Advanced Pancreatic NETs
December 1, 2014
Link to Abstract

A Review of the 2014 Annual ASCO Convention: Metformin and Other Chemotherapy for Pancreatic Cancer and NETs
July 28, 2014
Link to Abstract

Gleevec as Successful in Treating a Patient with a Neuroendocrine Tumor Containing the Kit Mutation
June 1, 2014
Link to Abstract

Metastatic pancreatic neuroendocrine tumors (pNET): placing current findings into perspective.

Phan AT. February 13, 2014
Link to Abstract

Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional database.
Ter-Minassian M, Chan JA, Hooshmand SM, Brais LK, Daskalova A, Heafield R, Buchanan L, Qian ZR, Fuchs CS, Lin X, Christiani DC, Kulke MH. January 14, 2014
Link to Abstract

Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT Within Patients with Gastroenteropancreatic Neuroendocrine Tumors.
Wild D, Bomanji JB, Benkert P, Maecke H, Ell PJ, Reubi JC, Caplin ME. January 7, 2014
Link to Abstract

PRRT as neoadjuvant treatment in NET.
Sowa-Staszczak A, Hubalewska-Dydejczyk A, Tomaszuk M. January 1, 2014
Link to Abstract

Synchronous resection of primary and liver metastases for neuroendocrine tumors.
Gaujoux S, Gonen M, Tang L, Klimstra D, Brennan MF, D’Angelica M, Dematteo R, Allen PJ, Jarnagin W, Fong Y.
Link to Abstract

Nonfunctional neuroendocrine tumor of the pancreas: Case report and review of the literature.
Amador Cano A, García F, Espinoza A, Bezies N, Herrera E, De Leija Portilla J. January 1, 2014
Link to Abstract

Circulating Tumor Cells As Prognostic Markers in Neuroendocrine Tumors.
Khan MS, Kirkwood A, Tsigani T, Garcia-Hernandez J, Hartley JA, Caplin ME, Meyer T. December 17, 2012
Link to Abstract

Small, nonfunctioning, asymptomatic pancreatic neuroendocrine tumors (PNETs): role for nonoperative management.
Lee LC, Grant CS, Salomao DR, Fletcher JG, Takahashi N, Fidler JL, Levy MJ, Huebner M. December 1, 2012
Link to Abstract

A Single Fasting Plasma 5-HIAA Value Correlates With 24-Hour Urinary 5-HIAA Values and Other Biomarkers in Midgut Neuroendocrine Tumors (NETs).
Tellez MR, Mamikunian G, O’Dorisio TM, Vinik AI, Woltering EA. November 15, 2012
Link to Abstract

FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3.
Hentic O, Hammel P, Couvelard A, Rebours V, Zappa M, Palazzo M, Maire F, Goujon G, Gillet A, Lévy P, Ruszniewski P. November 6. 2012
Link to Abstract

Lymph nodes and survival in pancreatic neuroendocrine tumors.
Krampitz GW, Norton JA, Poultsides GA, Visser BC, Sun L, Jensen RT. September 1, 2012
Link to Abstract

Neoadjuvant chemotherapy with capecitabine and temozolomide for unresectable pancreatic neuroendocrine tumor.
Devata S, Kim EJ. September 1, 2012
Link to Abstract

Pancreatic neuroendocrine tumors: radiographic calcifications correlate with grade and metastasis.

Poultsides GA, Huang LC, Chen Y, Visser BC, Pai RK, Jeffrey RB, Park WG, Chen AM, Kunz PL, Fisher GA, Norton JA. July 1, 2012
Link to Abstract

Pancreatic neuroendocrine tumors with involved surgical margins: prognostic factors and the role of adjuvant radiotherapy.
Arvold ND, Willett CG, Fernandez-del Castillo C, Ryan DP, Ferrone CR, Clark JW, Blaszkowsky LS, Deshpande V, Niemierko A, Allen JN, Kwak EL, Wadlow RC, Zhu AX, Warshaw AL, Hong TS. July 1, 2012
Link to Abstract

Feasibility and efficacy of combined cisplatin and irinotecan chemotherapy for poorly differentiated neuroendocrine carcinomas.
Nakano K, Takahashi S, Yuasa T, Nishimura N, Mishima Y, Sakajiri S, Yokoyama M, Tsuyama N, Ishikawa Y, Hatake K. August 1, 2012
Link to Abstract

Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors.
Chan JA, Stuart K, Earle CC, Clark JW, Bhargava P, Miksad R, Blaszkowsky L, Enzinger PC, Meyerhardt JA, Zheng H, Fuchs CS, Kulke MH. August 20, 2012
Link to Abstract

Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas.
Olsen IH, Sørensen JB, Federspiel B, Kjaer A, Hansen CP, Knigge U, Langer SW. August 22, 2012
Link to Abstract

FOLFIRI regimen, an effective second-line chemotherapy after failure of etoposide-platinum combination for patients with neuroendocrine carcinomas grade 3.
Hentic O, Hammel P, Couvelard A, Rebours V, Zappa M, Palazzo M, Maire F, Goujon G, Gillet A, Levy P, Ruszniewski P. August 31, 2012
Link to Abstract

Laparoscopic surgical exploration is an effective strategy for locating occult primary neuroendocrine tumors.

Massimino KP, Han E, Pommier SJ, Pommier RF.
Am J Surg. 2012 May;203(5):628-31. PMID: 22459446
Link to Abstract

Ki-67 predicts disease recurrence and poor prognosis in pancreatic neuroendocrine neoplasms.
Hamilton NA, Liu TC, Cavatiao A, Mawad K, Chen L, Strasberg SS, Linehan DC, Cao D, Hawkins WG.
Surgery. 2012 Apr 11. [Epub]  PMID: 22503317
Link to Abstract

Are contrast media required for (68)Ga-DOTATOC PET/CT in patients with neuroendocrine tumours of the abdomen?
Mayerhoefer ME, Schuetz M, Magnaldi S, Weber M, Trattnig S, Karanikas G.
Eur Radiol. 2012 Apr;22(4):938-46.  PMID: 22080251
Link to Abstract

Pancreatic Neuroendocrine Tumors With Involved Surgical Margins: Prognostic Factors and the Role of Adjuvant Radiotherapy.
Arvold ND, Willett CG, Fernandez-Del Castillo C, Ryan DP, Ferrone CR, Clark JW, Blaszkowsky LS, Deshpande V, Niemierko A, Allen JN, Kwak EL, Wadlow RC, Zhu AX, Warshaw AL, Hong TS.
Int J Radiat Oncol Biol Phys. 2012 Mar 11. [Epub]  PMID: 22414286
Link to Abstract

Pancreatic Neuroendocrine Tumors: Radiographic Calcifications Correlate with Grade and Metastasis.
Poultsides GA, Huang LC, Chen Y, Visser BC, Pai RK, Brooke Jeffrey R, Park WG, Chen AM, Kunz PL, Fisher GA, Norton JA.
Ann Surg Oncol. 2012 Mar 7. [Epub]  PMID: 22396008
Link to Abstract

EUS-FNA for pancreatic neuroendocrine tumors: a tertiary cancer center experience.
Atiq M, Bhutani MS, Bektas M, Lee JE, Gong Y, Tamm EP, Shah CP, Ross WA, Yao J, Raju GS, Wang X, Lee JH.
Dig Dis Sci. 2012 Mar;57(3):791-800. PMID: 21964743
Link to Abstract

Response to temozolomide and bevacizumab in a patient with poorly differentiated neuroendocrine carcinoma.
Lindholm DP, Eriksson B, Granberg D.
Med Oncol. 2012 Mar;29(1):301-3.  PMID: 2119166
Link to Abstract

The potential for induction peptide receptor chemoradionuclide therapy to render inoperable pancreatic and duodenal neuroendocrine tumours resectable.
Barber TW, Hofman MS, Thomson BN, Hicks RJ.
Eur J Surg Oncol. 2012 Jan;38(1):64-71.   PMID: 21906907
Link to Abstract

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study.
Pavel ME, Hainsworth JD, Baudin E, Peeters M, H�¶rsch D, Winkler RE, Klimovsky J, Lebwohl D, Jehl V, Wolin EM, Oberg K, Van Cutsem E, Yao JC; RADIANT-2 Study Group.
Lancet. 2011 Dec 10;378(9808):2005-12.  PMID: 22119496
Link to Abstract

The archaic distinction between functioning and nonfunctioning neuroendocrine neoplasms is no longer clinically relevant.
Modlin IM, Moss SF, Gustafsson BI, Lawrence B, Schimmack S, Kidd M.
Langenbecks Arch Surg. 2011 Dec;396(8):1145-56.  PMID: 21523447
Link to Abstract

A single institution experience of streptozocin/fluorouracil combination chemotherapy: a case series.
Naidoo J, O’Toole D, Kennedy MJ, Reynolds JV, O’Connor M, O’Byrne K.
Ir J Med Sci. 2011 Nov 3. [Epub ahead of print]  PMID: 22048868
Link to Abstract

Final results of a phase 2A study for the treatment of metastatic neuroendocrine tumors with a fixed activity of (90) Y-DOTA-D-Phe1-Tyr3 octreotide.
Savelli G, Bertagna F, Franco F, Dognini L, Bosio G, Migliorati E, Rodella C, Biasiotto G, Bettinsoli G, Minari C, Zaniboni A, Ferrari C, Tomassetti P, Ferrari V, Giubbini R.
Cancer. 2011 Oct 21. [Epub ahead of print]   PMID: 22020784
Link to Abstract

Phase II study of first-line FOLFIRI for progressive metastatic well-differentiated pancreatic endocrine carcinoma.
Brixi-Benmansour H, Jouve JL, Mitry E, Bonnetain F, Landi B, Hentic O, Bedenne L, Cadiot G.
Dig Liver Dis. 2011 Nov;43(11):912-6.  PMID: 21831734
Link to Abstract

EUS-FNA for Pancreatic Neuroendocrine Tumors: A Tertiary Cancer Center Experience.
Atiq M, Bhutani MS, Bektas M, Lee JE, Gong Y, Tamm EP, Shah CP, Ross WA, Yao J, Raju GS, Wang X, Lee JH.
Dig Dis Sci. 2011 Oct 1. [Epub]  PMID:  21964743
Link to Abstract

New therapeutic options for metastatic malignant insulinomas.
de Herder WW, van Schaik E, Kwekkeboom D, Feelders RA.
Clin Endocrinol (Oxf). 2011 Sep;75(3):277-84.
PMID: 21649688
Link to Abstract

Prognostic validity of a novel american joint committee on cancer staging classification for pancreatic neuroendocrine tumors.
Strosberg JR, Cheema A, Weber J, Han G, Coppola D, Kvols LK.
J Clin Oncol. 2011 Aug 1;29(22):3044-9.   PMID: 21709192
Link to Abstract

Tumor size correlates with malignancy in nonfunctioning pancreatic endocrine tumor.
Bettini R, Partelli S, Boninsegna L, Capelli P, Crippa S, Pederzoli P, Scarpa A, Falconi M.
Surgery. 2011 Jul;150(1):75-82.  PMID: 21683859
Link to Abstract

Response by Choi criteria to sunitinib plus octreotide LAR in a functional heavily pretreated advanced pancreatic neuroendocrine tumor.
Grande E, José Díez J, Pachón V, Angeles Vaz M, Longo F, Guillén C, García de Paredes ML, Carrato A.
Anticancer Drugs. 2011 Jun;22(5):477-9.  PMID: 21346550
Link to Abstract

Pancreatic endocrine tumors with major vascular abutment, involvement, or encasement and indication for resection.
Norton JA, Harris EJ, Chen Y, Visser BC, Poultsides GA, Kunz PC, Fisher GA, Jensen RT.
Arch Surg. 2011 Jun;146(6):724-32.  PMID: 21690450
Link to Abstract

Treatment with somatostatin analogues and chemoembolization of liver metastases for severe hypoglycemia in malignant insulinomas.
Maiza JC, Vezzosi D, Grunenwald S, Otal P, Guimbaud R, Bennet A, Caron P.
J Endocrinol Invest. 2011 May 27. [Epub]  PMID: 21623151
Link to Abstract

First-line treatment of patients with disseminated poorly differentiated neuroendocrine carcinomas with carboplatin, etoposide, and vincristine: A single institution experience.
Olsen IH, Langer SW, Jepsen I, Assens M, Federspiel B, Hasselby JP, Hansen CP, Kjær A, Knigge U.
Acta Oncol. 2011 May 26. [Epub]  PMID: 21615243
Link to Abstract

Implications of incidentally discovered, nonfunctioning pancreatic endocrine tumors: short-term and long-term patient outcomes.
Haynes AB, Deshpande V, Ingkakul T, Vagefi PA, Szymonifka J, Thayer SP, Ferrone CR, Wargo JA, Warshaw AL, Fernández-del Castillo C.
Arch Surg. 2011 May;146(5):534-8.   PMID: 21576607
Link to Abstract

Liver transplantation for hepatic metastases of neuroendocrine pancreatic tumors: a survival-based analysis.
Máthé Z, Tagkalos E, Paul A, Molmenti EP, Kóbori L, Fouzas I, Beckebaum S, Sotiropoulos GC.
Transplantation. 2011 Mar 15;91(5):575-82. PMID: 21200365
Link to Abstract

Everolimus for advanced pancreatic neuroendocrine tumors.
Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl
D, Öberg K; RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group.
N Engl J Med. 2011 Feb 10;364(6):514-23. PMID: 21306238

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Hörsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P.
N Engl J Med. 2011 Feb 10;364(6):501-13. PMID: 21306237
Link to Abstract

Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours.
Claringbold PG, Brayshaw PA, Price RA, Turner JH.
Eur J Nucl Med Mol Imaging. 2011 Feb;38(2):302-11. PMID: 21052661
Link to Abstract

First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.
Strosberg JR, Fine RL, Choi J, Nasir A, Coppola D, Chen DT, Helm J, Kvols L.
Cancer. 2011 Jan 15;117(2):268-75. Epub 2010 Sep 7. PMID: 20824724
Link to Abstract

Response to temozolomide and bevacizumab in a patient with poorly differentiated neuroendocrine carcinoma.
Lindholm DP, Eriksson B, Granberg D.
Med Oncol. 2010 Dec 30. [Epub] PMID: 21191667
Link to Abstract

Laparoscopic radiofrequency thermal ablation of neuroendocrine hepatic metastases: long-term follow-up.
Akyildiz HY, Mitchell J, Milas M, Siperstein A, Berber E.
Surgery. 2010 Dec;148(6):1288-93; discussion 1293. PMID: 21134563
Link to Abstract

Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis.
Mayo SC, de Jong MC, Pulitano C, Clary BM, Reddy SK, Gamblin TC, Celinksi SA, Kooby DA, Staley CA, Stokes JB, Chu CK, Ferrero A, Schulick RD, Choti MA, Mentha G, Strub J, Bauer TW, Adams RB, Aldrighetti L, Capussotti L, Pawlik TM.
Ann Surg Oncol. 2010 Dec;17(12):3129-36. 2010 Jun 29. [Epub] PMID: 20585879
Link to Abstract

Hepatic artery chemoembolization for the treatment of liver metastases from neuroendocrine tumors: a long-term follow-up in 123 patients.
Dong XD, Carr BI.
Med Oncol. 2010 Nov 24. [Epub] PMID: 21107755
Link to Abstract

Evaluation of the combination 5-Fluorouracil, dacarbazine, and epirubicin in patients with advanced well-differentiated neuroendocrine tumors.
Walter T, Bruneton D, Cassier PA, Hervieu V, Pilleul F, Scoazec JY, Chayvialle JA, Lombard-Bohas C.
Clin Colorectal Cancer. 2010 Oct 1;9(4):248-54.PMID: 20920998
Link to Abstract

First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.
Strosberg JR, Fine RL, Choi J, Nasir A, Coppola D, Chen DT, Helm J, KvolsL.
Cancer. 2010 Sep 7. [Epub] PMID: 20824724
Link to Abstract

Poorly differentiated endocrine carcinoma of the pancreas responded to gemcitabine: Case report.
Nakazuru S, Yoshio T, Suemura S, Itoh M, Araki M, Yoshioka C, Ohta M, Sueyoshi Y, Ohta T, Hasegawa H, Morita K, Toyama T, Kuzushita N, Kodama Y, Mano M, Mita E.
World J Gastroenterol. 2010 Aug 14;16(30):3853-6.PMID: 20698050
Link to Abstract

Pancreatic endocrine tumors less than 4 cm in diameter: resect or enucleate? a single-center experience.
Casadei R, Ricci C, Rega D, D’Ambra M, Pezzilli R, Tomassetti P, Campana D, Nori F, Minni F.
Pancreas. 2010 Aug;39(6):825-8.PMID: 20431423
Link to Abstract

Chromogranin A–biological function and clinical utility in neuro endocrine tumor disease.
Modlin IM, Gustafsson BI, Moss SF, Pavel M, Tsolakis AV, Kidd M.
Ann Surg Oncol. 2010 Mar 9. [Epub ahead of print]PMID: 20217257
Link to Abstract

Salvage therapy with (177)Lu-octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumors.
van Essen M, Krenning EP, Kam BL, de Herder WW, Feelders RA, Kwekkeboom DJ.
J Nucl Med. 2010 Mar;51(3):383-90. Epub 2010 Feb 11.PMID: 20150247
Link to Abstract

90Y-edotreotide for metastatic carcinoid refractory to octreotide.
Bushnell DL Jr, O’Dorisio TM, O’Dorisio MS, Menda Y, Hicks RJ, Van Cutsem E, Baulieu JL, Borson-Chazot F, Anthony L, Benson AB, Oberg K, Grossman AB, Connolly M, Bouterfa H, Li Y, Kacena KA, Lafrance N, Pauwels SA.
J Clin Oncol. 2010 Mar 1. [Epub ahead of print]PMID: 20194865
Link to Abstract

177Lu-[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategy.
Garkavij M, Nickel M, Sjögreen-Gleisner K, Ljungberg M, Ohlsson T, Wingårdh K, Strand SE, Tennvall J.
Cancer. 2010 Feb 15;116(4 Suppl):1084-92.PMID: 20127957
Link to Abstract

Treatment with tandem [(90)Y]DOTA-TATE and [(177)Lu] DOTA-TATE of neuroendocrine tumors refractory to conventional therapy: preliminary results.
Seregni E, Maccauro M, Coliva A, Castellani MR, Bajetta E, Aliberti G, Vellani C, Chiesa C, Martinetti A, Bogni A, Bombardieri E.
Q J Nucl Med Mol Imaging. 2010 Feb;54(1):84-91.PMID: 20168290
Link to Abstract

Efficacy of using a Standard Activity of (131)I-MIBG Therapy in Patients with Disseminated Neuroendocrine Tumours.
Navalkissoor S, Alhashimi DM, Quigley AM, Caplin ME, Buscombe JR.
Eur J Nucl Med Mol Imaging. 2009 Dec 17. [Epub ahead of print]PMID: 20016892
Link to Abstract

Neoadjuvant Peptide Receptor Radionuclide Therapy for an Inoperable Neuroendocrine Pancreatic Tumor.
Kaemmerer D, Prasad V, Daffner W, Hörsch D, Klöppel G, Hommann M, Baum RP.
World J Gastroenterol. 2009 Dec 14;15(46):5867-70.PMID: 19998512
Link to Abstract

A Successful Two-Stage Treatment with CDDP and CPT-11 for Pancreatic Neuroendocrine Carcinoma with Liver Metastasis.
Nomura S, Togawa A, Kaiho T, Shinmura K, Yanagisawa S, Okamoto R, Nishimura M, Tsuchiya S, Miyazaki M.
Gan To Kagaku Ryoho. 2009 Nov;36(11):1897-900. Japanese. PMID: 19920396
Link to Abstract

Refractory Neuroendocrine Tumor-Response to Liposomal Doxorubicin and Capecitabine.
Masi G, Fornaro L, Cupini S, Loupakis F, Vasile E, Baldi GG, Stasi I, Salvatore L, Falcone A.
Nat Rev Clin Oncol. 2009 Nov;6(11):670-4.PMID: 19861994
Link to Abstract

Combined Liver Surgery and RFA for Patients with Gastroenteropancreatic Endocrine Tumors Presenting with More Than 15 Metastases to the Liver.
Elias D, Goéré D, Leroux G, Dromain C, Leboulleux S, de Baere T, Ducreux
M, Baudin E.
Eur J Surg Oncol. 2009 Oct;35(10):1092-7. Epub 2009 May 21.PMID: 19464140
Link to Abstract

High-Dose Octreotide Acetate for Management of Gastroenteropancreatic Neuroendocrine Tumors.
Chadha MK, Lombardo J, Mashtare T, Wilding GE, Litwin A, Raczyk C, Gibbs JF, Kuvshinoff B, Javle MM, Iyer RV.
Anticancer Res. 2009 Oct;29(10):4127-30.PMID: 19846960
Link to Abstract

High-Administered Activity In-111 Octreotide Therapy with Concomitant Radiosensitizing 5FU Chemotherapy for Treatment of Neuroendocrine Tumors: Preliminary Experience.
Kong G, Johnston V, Ramdave S, Lau E, Rischin D, Hicks RJ.
Cancer Biother Radiopharm. 2009 Oct;24(5):527-33.PMID: 19877882
Link to Abstract

Pancreatic Islet Cell Carcinoma Presenting with Concurrent Cushing’s and Zollinger-Ellison Syndromes: Case Series and Literature Review.
Said R, O’reilly EM, Blumgart L, Shia J, Abou-Alfa GK.
Eur J Gastroenterol Hepatol. 2009 Sep 18. [Epub]. PMID: 19770666
Link to Abstract

Detection of Unknown Primary Neuroendocrine Tumours (CUP-NET) using (68)Ga-DOTA-NOC Receptor PET/CT.
Prasad V, Ambrosini V, Hommann M, Hoersch D, Fanti S, Baum RP.
Eur J Nucl Med Mol Imaging. 2009 Jul 18. [Epub]. PMID: 19618183
Link to Abstract

Successful Control of Intractable Hypoglycemia Using Rapamycin in an 86-year old man with a Pancreatic Insulin-Secreting Islet Cell Tumor and Metastases.
Bourcier ME, Sherrod A, Diguardo M, Vinik AI.
J Clin Endocrinol Metab. 2009 Jun 30. [Epub] PMID: 19567519
Link to Abstract

Staged Surgery with Neoadjuvant (90)Y-DOTATOC Therapy for Down-Sizing Synchronous Bilobular Hepatic Metastases from a Neuroendocrine Pancreatic Tumor.
Stoeltzing O, Loss M, Huber E, Gross V, Eilles C, Mueller-Brand J, Schlitt HJ.
Langenbecks Arch Surg. 2009 Jun 9. [Epub] PMID: 19506898
Link to Abstract

Prolonged Survival After Hepatic Artery Embolization in Patients with Midgut Carcinoid Syndrome.
Swärd C, Johanson V, Nieveen van Dijkum E, Jansson S, Nilsson O, Wängberg B, Ahlman H, Kölby L.
Br J Surg. 2009 May;96(5):517-21. PMID: 19358175
Link to Abstract

Laparoscopic Surgery for Pancreatic Insulinomas: A Single-Institution Experience of 29 Cases.
Luo Y, Liu R, Hu MG, Mu YM, An LC, Huang ZQ. J Gastrointest Surg. 2009
May;13(5):945-50. PMID: 19224293
Link to Abstract

Liver Resection Versus Other Treatments for Neuroendocrine Tumours in Patients with Resectable Liver Metastases.
Gurusamy KS, Ramamoorthy R, Sharma D, Davidson BR.
Cochrane Database Syst Rev. 2009 Apr 15;(2):CD007060. PMID: 19370671
Link to Abstract

Development of the Norfolk Quality of Life Tool for Assessing Patients with Neuroendocrine Tumors.
Vinik E, Carlton CA, Silva MP, Vinik AI.
Pancreas. 2009 Apr;38(3):e87-95. PMID: 19276865
Link to Abstract

Radiotherapy for Pancreatic Neuroendocrine Tumors.
Contessa JN, Griffith KA, Wolff E, Ensminger W, Zalupski M, Lawrence TS, Ben-Josef E.
Int J Radiat Oncol Biol Phys. 2009 Mar 25 [Epub]. PMID: 19327905
Link to Abstract

A Rare Surgical Case of Multiple Liver Resections for Recurrent Liver Metastases from Pancreatic Gastrinoma: Liver and Vena Cava Resection.
Pachera S, Yokoyama Y, Nishio H, Oda K, Ebata T, Igami T, Abe T, Shingu Y, Nagino M.
J Hepatobiliary Pancreat Surg. 2009 Mar 10 [Epub]. PMID: 19267257
Link to Abstract

Management of the Primary Tumor in Patients with Metastatic Pancreatic Neuroendocrine Tumor: A Contemporary Single-Institution Review.
Bruzoni M, Parikh P, Celis R, Are C, Ly QP, Meza JL, Sasson AR.
Am J Surg. 2009 Mar;197(3):376-81. PMID: 19245918
Link to Abstract

Reclassification of Neuroendocrine Tumors Improves the Separation of Carcinoids and the Prediction of Survival.
Skov BG, Krasnik M, Lantuejoul S, Skov T, Brambilla E.
J Thorac Oncol. 2008 Dec;3(12):1410-5. PMID: 19057265
Link to Abstract

Combination Therapy with Histone Deacetylase Inhibitors and Lithium Chloride: A Novel Treatment for Carcinoid Tumors.
Adler JT, Hottinger DG, Kunnimalaiyaan M, Chen H.
Ann Surg Oncol. 2008 Nov 22. [Epub]. PMID: 19030935
Link to Abstract

Intraoperative Hand Held Gamma Probe Detection of a Recurrent Nonfunctional Neuroendocrine Tumor.
Van Haren RM, Fitzgerald TL.
JOP. 2008 Nov 3;9(6):704-7. PMID: 18981551
Link to Abstract

Laparoscopic Enucleation of a Nonfunctioning Neuroendocrine Tumor of the Pancreas.
Kang CM, Lee KG, Pyo JY, Lee SW, Kim KS, Choi JS, Lee WJ, Kim BR.
Yonsei Med J. 2008 Oct 31;49(5):864-8. PMID: 18972611
Link to Abstract

Surgical Approach and Perioperative Complications Determine Short-Term Outcomes in Patients with Insulinoma: Results of a Bi-Institutional Study.
Roland CL, Lo CY, Miller BS, Holt S, Nwariaku FE.
Ann Surg Oncol. 2008 Sep 30. [Epub] PMID: 18825460
Link to Abstract

Clinical Applications of 68Ga-DOTANOC in Neuroendocrine Tumours.
Lopci E, Nanni C, Rampin L, Rubello D, Fanti S.
Minerva Endocrinol. 2008 Sep;33(3):277-81. PMID: 18846030
Link to Abstract

Risk Factors Associated with Neuroendocrine Tumors: A U.S.-Based Case-Control Study.
Hassan MM, Phan A, Li D, Dagohoy CG, Leary C, Yao JC.
Int J Cancer. 2008 Aug 15;123(4):867-73. PMID: 18491401
Link to Abstract

Radioembolization with Selective Internal radiation Microspheres for Neuroendocrine Liver Metastases.
King J, Quinn R, Glenn DM, Janssen J, Tong D, Liaw W, Morris DL.
Cancer. 2008 Jul 10. PMID: 18618495
Link to Abstract

Activity of Sunitinib in Patients with Advanced Neuroendocrine Tumors.
Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, Bergsland E, Stuart K, Tye L, Huang X, Li JZ, Baum CM, Fuchs CS.<
J Clin Oncol. 2008 Jul 10;26(20):3403-10. PMID: 18612155
Link to Abstract

Prognostic Factors of Long-Term Outcome in Gastroenteropancreatic Neuroendocrine Tumours.
Pape UF, Berndt U, Mueller-Nordhorn J, Boehmig M, Roll S, Koch M, Willich S, Wiedenmann B.
Endocr Relat Cancer. 2008 Jul 4. PMID: 18603570
Link to Abstract

Clinical Value of Monitoring Plasma Octreotide Levels During Chronic Octreotide Long-Acting Repeatable Therapy in Carcinoid Patients.
Woltering EA, Salvo VA, O’Dorisio TM, Lyons J 3rd, Li G, Zhou Y, Seward JR, Go VL, Vinik AI, Mamikunian P, Mamikunian G.
Pancreas. 2008 Jul;37(1):94-100. PMID: 18580450
Link to Abstract

Selective Hepatic arterial Infusion of In-111-DTPA-Phe(1)-Octreotide in Neuroendocrine Liver Metastases.
Limouris GS, Chatziioannou A, Kontogeorgakos D, Mourikis D, Lyra M, Dimitriou P, Stavraka A, Gouliamos A, Vlahos L.
Eur J Nucl Med Mol Imaging. 2008 Jun 7. [Epub ahead of print] PMID: 18536916
Link to Abstract

Radioembolization for Unresectable Neuroendocrine Hepatic Metastases Using Resin 90Y-Microspheres: Early Results in 148 Patients.
Kennedy AS, Dezarn WA, McNeillie P, Coldwell D, Nutting C, Carter D, Murthy R, Rose S, Warner RR, Liu D, Palmedo H, Overton C, Jones B, Salem R.
Am J Clin Oncol. 2008 Jun;31(3):271-9. PMID: 18525307
Link to Abstract

Risk Factors Associated with Neuroendocrine Tumors: A U.S.-Based Case-Control Study.
Hassan MM, Phan A, Li D, Dagohoy CG, Leary C, Yao JC.
Int J Cancer. 2008 May 19. [Epub]PMID: 18491401
Link to Abstract

Radiolabeled DOTATOC in Patients with Advanced Paraganglioma and Pheochromocytoma.
Forrer F, Riedweg I, Maecke HR, Mueller-Brand J.
Q J Nucl Med Mol Imaging. 2008 May 16. [Epub]PMID: 18480742
Link to Abstract

Primary Tumour Resection in Metastatic Nonfunctioning Pancreatic Endocrine Carcinomas.
Bettini R, Mantovani W, Boninsegna L, Crippa S, Capelli P, Bassi C, Scarpa A, Pederzoli P, Falconi M.
Dig Liver Dis. 2008 May 5. [Epub] PMID: 18463008
Link to Abstract

Treatment with the Radiolabeled Somatostatin Analog [177 Lu-DOTA 0,Tyr3]Octreotate: Toxicity, Efficacy, and Survival.
Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, Feelders RA, van Aken MO, Krenning EP.
J Clin Oncol. 2008 May 1;26(13):2124-30. PMID: 18445841
Link to Abstract

Surgery and Radiofrequency Ablation for Treatment of Liver Metastases from Midgut and Foregut Carcinoids and Endocrine Pancreatic Tumors.
Eriksson J, Stålberg P, Nilsson A, Krause J, Lundberg C, Skogseid B, Granberg D, Eriksson B, Akerström G, Hellman P.
World J Surg. 2008 May;32(5):930-8. PMID: 18324347
Link to Abstract

Comparison Between (68)Ga-DOTA-NOC and (18)F-DOPA PET for the Detection of Gastro-Entero-Pancreatic and Lung Neuro-Endocrine Tumours.
Ambrosini V, Tomassetti P, Castellucci P, Campana D, Montini G, Rubello D, Nanni C, Rizzello A, Franchi R, Fanti S.
Eur J Nucl Med Mol Imaging. 2008 Apr 17. [Epub]PMID: 18418596
Link to Abstract

Requiem for the Term ‘Carcinoid Tumour’ in the Gastrointestinal Tract?
Chetty R.
Can J Gastroenterol. 2008 Apr;22(4):357-8. PMID: 18414708
Link to Abstract

Improved Staging of Patients with Carcinoid and Islet Cell Tumors with 18F-Dihydroxy-Phenyl-Alanine and 11C-5-Hydroxy-Tryptophan Positron Emission Tomography.
http://www.ncbi.nlm.nih.gov/pubmed/18349401
J Clin Oncol. 2008 Mar 20;26(9):1489-95. PMID: 18349401
Link to Abstract

Pancreatic Cystic Neuroendocrine Tumors: Preoperative Diagnosis with Endoscopic Ultrasound and Fine-Needle Immunocytology.
Baker MS, Knuth JL, Dewitt J, Leblanc J, Cramer H, Howard TJ, Schmidt CM, Lillemoe KD, Pitt HA.
J Gastrointest Surg. 2008 Mar;12(3):450-6. PMID: 18157720
Link to Abstract

6-L-18F-Fluorodihydroxyphenylalanine PET in Neuroendocrine Tumors: Basic Aspects and Emerging Clinical Applications.
Jager PL, Chirakal R, Marriott CJ, Brouwers AH, Koopmans KP, Gulenchyn KY.
J Nucl Med. 2008 Apr;49(4):573-86. 2008 Mar 14. [Epub] PMID: 18344441
Link to Abstract

Targeting Vascular Endothelial Growth Factor in Advanced Carcinoid Tumor: A Random Assignment Phase II Study of Depot Octreotide with Bevacizumab and Pegylated Interferon Alpha-2b.
Yao JC, Phan A, Hoff PM, Chen HX, Charnsangavej C, Yeung SC, Hess K, Ng C, Abbruzzese JL, Ajani JA.
J Clin Oncol. 2008 Mar 10;26(8):1316-23. PMID: 18323556
Link to Abstract

Prognostic Score Predicting Survival after Resection of Pancreatic Neuroendocrine Tumors: Analysis of 3851 Patients.
Bilimoria KY, Talamonti MS, Tomlinson JS, Stewart AK, Winchester DP, Ko CY, Bentrem DJ.
Ann Surg. 2008 Mar;247(3):490-500. PMID: 18376195
Link to Abstract

Evaluation of Unusual Neuroendocrine Tumours by Means of (68)Ga-DOTA-NOC PET.
Fanti S, Ambrosini V, Tomassetti P, Castellucci P, Montini G, Allegri V, Grassetto G, Rubello D, Nanni C, Franchi R.
Biomed Pharmacother. 2008 Mar 3. [Epub] PMID: 18358680
Link to Abstract

Antitumor Activity of Rapamycin and Octreotide as Single Agents or in Combination in Neuroendocrine Tumors.
Moreno A, Akcakanat A, Munsell MF, Soni A, Yao JC, Meric-Bernstam F.
Endocr Relat Cancer. 2008 Mar;15(1):257-66. PMID: 18310292
Link to Abstract

Complete Response of CNS-Involved Olfactory Neuroendocrine Tumor using Multimodal Therapy.
Ahuja G, Cuellar S, Choudhry I, Setty S, Yao M, Villano JL.
Onkologie. 2008 Mar;31(3):119-21. PMID: 18322415
Link to Abstract

Assessment of the Efficacy and Toxicity of (131)I-Metaiodobenzylguanidine Therapy for Metastatic Neuroendocrine Tumours.
Nwosu AC, Jones L, Vora J, Poston GJ, Vinjamuri S, Pritchard DM.
Br J Cancer. 2008 Feb 19. PMID: 18283308
Link to Abstract

Treatment with Combined Streptozotocin and Liposomal Doxorubicin in Metastatic Endocrine Pancreatic Tumors.
Fjällskog ML, Janson ET, Falkmer UG, Vatn MH, Oberg KE, Eriksson BK.
Neuroendocrinology. 2008 Feb 18. PMID: 18285678
Link to Abstract

Is Laparoscopic Resection Adequate in Patients with Neuroendocrine Pancreatic Tumors?
Fernández-Cruz L, Blanco L, Cosa R, Rendón H.
World J Surg. 2008 Feb 11. PMID: 18264824
Link to Abstract

Islet 1 (Isl1) Expression is a Reliable Marker for Pancreatic Endocrine Tumors and Their Metastases.
Schmitt AM, Riniker F, Anlauf M, Schmid S, Soltermann A, Moch H, Heitz PU, Klöppel G, Komminoth P, Perren A.
Am J Surg Pathol. 2008 Feb 5. PMID: 18300808
Link to Abstract

Transcatheter Arterial Chemoembolization (TACE) Using Degradable Starch Microspheres (DSM) (DSM-TACE) for Primary and Metastatic Liver Neuroendocrine Tumors from Gastrointestinal Neuroendocrine Tumors.
Fujisaki T, Ikari T, Kamei A, Takano K, Kuraoka K, Yoshimoto K, Hirasawa T, Asahara S.
Nippon Shokakibyo Gakkai Zasshi. 2008 Feb;105(2):206-13. PMID: 18250591
Link to Abstract

Prognostic Factors at Diagnosis and Value of WHO Classification in a Mono-Institutional Series of 180 Non-Functioning Pancreatic Endocrine Tumours.
Bettini R, Boninsegna L, Mantovani W, Capelli P, Bassi C, Pederzoli P, Delle Fave GF, Panzuto F, Scarpa A, Falconi M.
Ann Oncol. 2008 Jan 21. PMID: 18209014
Link to Abstract

Report on Short-Term Side Effects of Treatments with (177)Lu-Octreotate in Combination with Capecitabine in Seven Patients with Gastroenteropancreatic Neuroendocrine Tumours.
van Essen M, Krenning EP, Kam BL, de Herder WW, van Aken MO, Kwekkeboom DJ.
Eur J Nucl Med Mol Imaging. 2008 Jan 11. PMID: 18188559
Link to Abstract

Laparoscopic vs Open Resection of Pancreatic Endocrine Neoplasms: Single Institution’s Experience over 14 Years.
Gumbs AA, Grès P, Madureira F, Gayet B.
Langenbecks Arch Surg. 2008 Jan 10. PMID: 18196267
Link to Abstract

Results Following Surgical Resection for Malignant Pancreatic Neuroendocrine Tumours. A Single Institutional Experience.
Bonney GK, Gomez D, Rahman SH, Verbeke CS, Prasad KR, Toogood GJ, Lodge JP, Menon KV.
JOP. 2008 Jan 8;9(1):19-25. PMID: 18182738
Link to Abstract

Functional MRI Evaluation of Tumor Response in Patients with Neuroendocrine Hepatic Metastasis Treated with Transcatheter Arterial Chemoembolization.
Liapi E, Geschwind JF, Vossen JA, Buijs M, Georgiades CS, Bluemke DA, Kamel IR.
AJR Am J Roentgenol. 2008 Jan;190(1):67-73. PMID: 18094295
Link to Abstract

Thymic Carcinoid Responds to Neoadjuvant Therapy with Sunitinib and Octreotide: A Case Report.
Dham A, Truskinovsky AM, Dudek AZ.
J Thorac Oncol. 2008 Jan;3(1):94-7. PMID: 18166847
Link to Abstract

Improved Contemporary Surgical Management of Insulinomas: A 25-Year Experience at the Massachusetts General Hospital.
Nikfarjam M, Warshaw AL, Axelrod L, Deshpande V, Thayer SP, Ferrone CR, Fernández-del Castillo C.
Ann Surg. 2008 Jan;247(1):165-72. PMID: 18156937
Link to Abstract

Pancreatic Neuroendocrine Tumours.
Alexakis N, Neoptolemos JP.
Best Pract Res Clin Gastroenterol. 2008;22(1):183-205. PMID: 18206821
Link to Abstract

Diagnostic Value of CDX-2 and TTF-1 Expressions in Separating Metastatic Neuroendocrine Neoplasms of Unknown Origin.
Lin X, Saad RS, Luckasevic TM, Silverman JF, Liu Y.
Appl Immunohistochem Mol Morphol. 2007 Dec;15(4):407-14. PMID: 18091383
Link to Abstract

Use of Octreotide for the Prevention of Pancreatic Fistula after Elective Pancreatic Surgery: A Systematic Review and Meta-Analysis.
Alghamdi AA, Jawas AM, Hart RS.
Can J Surg. 2007 Dec;50(6):459-66. Review. PMID: 18053374
Link to Abstract

Laparoscopic Enucleation of Insulinomas.
Sweet MP, Izumisato Y, Way LW, Clark OH, Masharani U, Duh QY.
Arch Surg. 2007 Dec;142(12):1202-4; discussion 1205. PMID: 18086988
Link to Abstract

Strategy for the Surgical Management of Insulinomas: Analysis of 52 Cases.
Liu H, Peng C, Zhang S, Wu Y, Fang H, Sheng H, Peng S.
Dig Surg. 2007;24(6):463-70. Epub 2007 Nov 29. PMID: 18057893
Link to Abstract

Clinicopathologic Features and Treatment Trends of Pancreatic Neuroendocrine Tumors: Analysis of 9,821 Patients.
Bilimoria KY, Tomlinson JS, Merkow RP, Stewart AK, Ko CY, Talamonti MS, Bentrem DJ.
J Gastrointest Surg. 2007 Nov;11(11):1460-7; discussion 1467-9. Epub 2007 Sep 11. PMID: 17846854
Link to Abstract

Diagnosis and Treatment of Gastric Neuroendocrine Tumours.
Plöckinger U.
Wien Klin Wochenschr. 2007 Nov;119(19-20):570-572. PMID: 17985089
Link to Abstract

Diagnosis and Treatment of Gastrinoma in the Era of Proton Pump Inhibitors.
Banasch M, Schmitz F.
Wien Klin Wochenschr. 2007 Nov;119(19-20):573-578. PMID: 17985090
Link to Abstract

Management of Sporadic and Multiple Endocrine Neoplasia Type 1 Gastrinomas.
Fendrich V, Langer P, Waldmann J, Bartsch DK, Rothmund M.
Br J Surg. 2007 Nov;94(11):1331-41. PMID: 17939142
Link to Abstract

Type 1 and 2 Gastric Carcinoid Tumors: Long-Term Follow-up of the Efficacy of Treatment with a Slow-Release Somatostatin Analogue.
Manfredi S, Pagenault M, de Lajarte-Thirouard AS, Bretagne JF.
Eur J Gastroenterol Hepatol. 2007 Nov;19(11):1021-5. PMID: 18049175
Link to Abstract

The Role of Somatostatin Analogues in the Treatment of Neuroendocrine Tumours.
Grozinsky-Glasberg S, Grossman AB, Korbonits M.
Mol Cell Endocrinol. 2007 Oct 13. PMID: 18037561
Link to Abstract

Embolization of an Insulinoma of the Pancreas with Trisacryl Gelatin Microspheres as Definitive Treatment.
Rott G, Biggemann M, Pfohl M.
Cardiovasc Intervent Radiol. Epub 2007 Oct 6. PMID: 17922161
Link to Abstract

Diagnosis and Surgical Treatment of Pancreatic Endocrine Tumors in 36 Patients: A Single-Center Report
Liu H, Zhang SZ, Wu YL, Fang HQ, Li JT, Sheng HW, Wang Y.
Chin Med J (Engl). 2007 Sep 5;120(17):1487-90. PMID: 17908455
Link to Abstract

Endocrine Pancreatic Tumors with Glucagon Hypersecretion: A Retrospective Study of 23 Cases During 20 Years.
Kindmark H, Sundin A, Granberg D, Dunder K, Skogseid B, Janson ET, Welin S, Oberg K, Eriksson B.
Med Oncol. 2007;24(3):330-7. PMID: 17873310
Link to Abstract

RadioFrequency Thermal Ablation of Metastatic Neuroendocrine Tumors in the Liver.
Mazzaglia PJ, Berber E, Siperstein AE.
Curr Treat Options Oncol. 2007 Aug;8(4):322-30. PMID: 18084730
Link to Abstract

Effective Treatment of Locally Advanced Endocrine Tumors of the Pancreas with Chemoradiotherapy.
Strosberg J, Hoffe S, Gardner N, Choi J, Kvols L.
Neuroendocrinology. 2007;85(4):216-20. PMID: 17541257
Link to Abstract

Successful Pancreatectomy with En-Bloc Resection of the Celiac Artery and Portal Vein for Pancreatic Endocrine Carcinoma.
Akatsu T, Aiura K, Shimazu M, Ueda M, Wakabayashi G, Tanabe M, Kawachi S, Shinoda M, Kameyama K, Kitajima M, Kitagawa Y.
Hepatogastroenterology. 2007 Jun;54(76):1269-71. PMID: 17629086
Link to Abstract

Magnetic poly epsilon-caprolactone nanoparticles containing Fe3O4 and gemcitabine enhance anti-tumor effect in pancreatic cancer xenograft mouse model.
Gang J, Park SB, Hyung W, Choi EH, Wen J, Kim HS, Shul YG, Haam S, Song SY.
J Drug Target. 2007 Jul;15(6):445-53. PMID: 17613663
Link to Abstract

Aggressive Pancreatic Resection for Primary Pancreatic Neuroendocrine Tumor: Is it Justifiable?
Teh SH, Deveney C, Sheppard BC.
Am J Surg. 2007 May;193(5):610-3; discussion 613. Oregon Health and Science University, Portland, Oregon.
Link to Abstract

Comparison of (68)Ga-DOTATOC PET and (111)In-DTPAOC (Octreoscan) SPECT in Patients with Neuroendocrine Tumours.
Buchmann I, Henze M, Engelbrecht S, Eisenhut M, Runz A, Schafer M, Schilling T, Haufe S, Herrmann T, Haberkorn U.
Eur J Nucl Med Mol Imaging. 2007 May 23. University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.
Link to Abstract

Temozolomide as Monotherapy is Effective in Treatment of Advanced Malignant Neuroendocrine Tumors.
Ekeblad S, Sundin A, Janson ET, Welin S, Granberg D, Kindmark H, Dunder K, Kozlovacki G, Orlefors H, Sigurd M, Oberg K, Eriksson B, Skogseid B.
Clin Cancer Res. 2007 May 15;13(10):2986-91. Uppsala University, Uppsala, Sweden
Link to Abstract

68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy And CT.
Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, Kovacs P, Von Guggenberg E, Bale R, Virgolini IJ.
J Nucl Med. 2007 Apr;48(4):508-18. Innsbruck Medical University, Innsbruck, Austria.
Link to Abstract

Surgery in Malignant Pancreatic Neuroendocrine Tumors.
Nguyen SQ, Angel LP, Divino CM, Schluender S, Warner RR.
J Surg Oncol. 2007 Apr 27. The Mount Sinai School of Medicine, New York, New York.
Link to Abstract

Surgical Strategies and Predictors of Outcome for Malignant Neuroendocrine Tumors of the Pancreas.
Bahra M, Jacob D, Pascher A, Plockinger U, Kristiansen G, Neuhaus P, Langrehr JM.
J Gastroenterol Hepatol. 2007 Apr 19. Humboldt University, Berlin, Germany.
Link to Abstract

Biochemistry of Neuroendocrine Tumours.
de Herder WW.
Best Pract Res Clin Endocrinol Metab. 2007 Mar;21(1):33-41. Sector of Endocrinology, Erasmus MC, 3015 CE Rotterdam, The Netherlands.
Link to Abstract

Imaging of Neuroendocrine Tumours (CT/MR/US).
Rockall AG, Reznek RH.
Best Pract Res Clin Endocrinol Metab. 2007 Mar;21(1):43-68. St Bartholomew’s Hospital, Dominion House, Bartholomew Close, West Smithfield, London, UK.
Link to Abstract

Race, Socioeconomic Status, Treatment, and Survival Time among Pancreatic Cancer Cases in California.
Zell JA, Rhee JM, Ziogas A, Lipkin SM, Anton-Culver H.
Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):546-52. University of California, Irvine Medical Center, Orange, California, USA
Link to Abstract

Surgery on Neuroendocrine Tumours.
Akerstrom G, Hellman P.
Best Pract Res Clin Endocrinol Metab. 2007 Mar;21(1):87-109. University Hospital, SE-751 85 Uppsala, Sweden.
Link to Abstract

Aggressive Surgery Improves Long-Term Survival in Neuroendocrine Pancreatic Tumors: An Institutional Experience.
Schurr PG, Strate T, Rese K, Kaifi JT, Reichelt U, Petri S, Kleinhans H, Yekebas EF, Izbicki JR.
Ann Surg. 2007 Feb;245(2):273-81. University Medical Center of Hamburg-Eppendorf, University of Hamburg, Germany.
Link to Abstract

Clinical and In Vitro Studies of Imatinib in Advanced Carcinoid Tumors.
Yao JC, Zhang JX, Rashid A, Yeung SC, Szklaruk J, Hess K, Xie K, Ellis L, Abbruzzese JL, Ajani JA.
Clin Cancer Res. 2007 Jan 1;13(1):234-40. The University of Texas / M.D. Anderson Cancer Center, Houston, Texas.
Link to Abstract

An Aggressive Surgical Approach Leads to Long-Term Survival in Patients with Pancreatic Endocrine Tumors.
Fendrich V, Langer P, Celik I, Bartsch DK, Zielke A, Ramaswamy A, Rothmund M.
Ann Surg. 2006 Dec;244(6):845-51; discussion 852-3. Philipps-University Marburg, Germany.
Link to Abstract

Are Capecitabine and Oxaliplatin (XELOX) Suitable Treatments for Progressing Low-Grade and High-Grade Neuroendocrine Tumours?
Bajetta E, Catena L, Procopio G, De Dosso S, Bichisao E, Ferrari L, Martinetti A, Platania M, Verzoni E, Formisano B, Bajetta R.
Cancer Chemother Pharmacol. 2006 Aug 26; [Epub]. Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy.
Link to Abstract

Resection of Pancreatic Neuroendocrine Tumors: Results of 70 Cases.
Kazanjian KK, Reber HA, Hines OJ.
Arch Surg. 2006 Aug;141(8):765-9; discussion 769-70. University of California, Los Angeles.
Link to Abstract

Liver Transplantation for Patients with Metastatic Endocrine Tumors: Single-Center Experience with 15 Patients.
Frilling A, Malago M, Weber F, Paul A, Nadalin S, Sotiropoulos GC, Cicinnati V, Beckebaum S, Bockisch A, Mueller-Brand J, Hofmann M, Schmid KW, Gerken G, Broelsch CE.
Liver Transpl. 2006 Jul;12(7):1089-96. University Hospital Essen, Essen, Germany
Link to Abstract

Survival and Response after Peptide Receptor Radionuclide Therapy with [90Y-DOTA0,Tyr3]Octreotide in Patients with Advanced Gastroenteropancreatic Neuroendocrine Tumors.
Valkema R, Pauwels S, Kvols LK, Barone R, Jamar F, Bakker WH, Kwekkeboom DJ, Bouterfa H, Krenning EP.
Semin Nucl Med. 2006 Apr;36(2):147-56. Department of Nuclear Medicine, Erasmus MC, Rotterdam, the Netherlands.
Link to Abstract

Efficacy and Tolerability of Pegylated IFN-alpha in Patients with Neuroendocrine Gastroenteropancreatic Carcinomas.
Pavel ME, Baum U, Hahn EG, Schuppan D, Lohmann T.
J Interferon Cytokine Res. 2006 Jan;26(1):8-13. University Hospital Erlangen-Nuremberg, 91054 Erlangen, Germany.
Link to Abstract

Phase II Study 0f Temozolomide and Thalidomide in Patients with Metastatic Neuroendocrine Tumors.
Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, Vincitore M, Michelini A, Fuchs CS.
J Clin Oncol. 2006 Jan 20;24(3):401-6. Dana-Farber Cancer Institute, Boston, Massachusetts.
Link to Abstract

The Role of Cytoreductive Hepatic Surgery as an Adjunct to the Management of Metastatic Neuroendocrine Carcinomas.
Hodul P, Malafa M, Choi J, Kvols L.
Cancer Control. 2006 Jan;13(1):61-71. H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.
Link to Abstract

Targeted Radionuclide Therapy with 90Y-DOTATOC in Patients with Neuroendocrine Tumors.
Forrer F, Waldherr C, Maecke HR, Mueller-Brand J.
Anticancer Res. 2006 Jan-Feb;26(1B):703-7. University Hospital Basel, Switzerland.
Link to Abstract